THE SULTON PEDIATRIC GROUP, PC
5700 HILLANDALE DR
SUITE 150
July 01, 1999
A phase II study of combined-modality treatment consisting of uracil and tegafur (in a molar ratio of 4:1 [UFT]) plus cisplatin (Platinol) and concurrent radiotherapy was conducted to evaluate the activity of this regimen in